What Is in a Name? 1691 because of changes in the redox state of the cell. More experimentation is needed to clarify the mechanism of AIBP as related to angiogenesis. A brief summary of what is known about AIBP is included in the Table. 
T
he article by Mao et al 1 shows that apolipoprotein A-I binding protein (AIBP) limits angiogenesis through regulation of Notch 1 signaling. Deletion of AIBP increased vascular density and improved perfusion in a murine ischemia model. AIBP expression was increased in patients with ischemic cardiomyopathy. In an independent study, this protein, renamed NAXE, has been shown to participate in recovering S-tetrahydro-nicotinamide adenine dinucleotide (S-NADHX) by epimerizing R-NADHX. So the question becomes how does an enzyme that participates in metabolite repair by recovering reducing intracellular equivalents participate in angiogenesis?
Article, see p 1727
AIBP has been reported to avidly bind apolipoprotein A-1 (apoA-I), the principal protein component of high-density lipoprotein (HDL). Loss of AIBP was found to accelerate angiogenesis without affecting the integrity of vessel walls. Using Apoa1bp −/− mice, the present article has provided evidence that AIBP plays a role in angiogenesis that involves cholesterol metabolism and Notch signaling. 1 These studies suggest that AIBP downregulates Notch 1 by a process that depends on γ-secretase activity. γ-Secretase is an intramembrane protease complex composed of 4 integral membrane proteins: APH1 (anterior pharynx-defective 1 protein), nicastrin, PEN2 (presenilin enhancer 2), and presenilin. Intramembrane proteolysis is highly conserved process for cell signaling. Presenilin cleaves only proteins that have a single transmembrane component with the C-terminus cytoplasmic and the N-terminus extracellular. The activation process is initiated by extracellular proteolysis empolying a sheddase. For example, ADAM metallopeptidase domain 17 removes the extracellular portion of the Notch1 receptor followed by intracellular presenilin proteolysis and release of the Notch1 intracellular domain, which signals through translocation to the nucleus or binding to other cytosolic proteins. 2, 3 The current article does not show a direct interaction between AIBP and the various proteins that regulate angiogenesis (eg, Notch1, VEGFR2 [vascular endothelial growth factor receptor 2], or γ-secretase). However, treatment of human retinal microvascular endothelial cells with HDL 3 plus AIBP showed significant translocation of Notch1 from raft fractions to nonraft fractions. Previous studies have suggested that γ-secretase was more active in releasing NICD when localized to nonraft regions of the membrane. Because raft regions are enriched in cholesterol, processes that remove cholesterol will reduce the fraction of membrane that exists as lipid rafts (eg, incubating cells with methyl-β-cyclodextrin). When NICD release was studied in human retinal microvascular endothelial cells, AIBP or HDL 3 were not particularly active by themselves, but a combination of AIBP and HDL 3 was as effective as 10 mmol/L methyl-β-cyclodextrin in increasing NICD.
In other studies reported here, the authors show that increased HDL levels can reduce angiogenesis. Apoa1b −/− mice crossed with apoA-I transgenic mice had higher levels of HDL and did not display the proangiogenic phenotype seen in Apoa1bp −/− mice. Consistent with this observation, they report that NICD levels were elevated and VEGFR2 phosphorylation reduced, a mechanistic indication that angiogenesis was inhibited.
However, there may be more to the mechanism of action of AIBP. The APOA1BP gene that codes AIBP was recently renamed NAXE by the Human Gene Organization Gene Nomenclature Committee. This protein has been well studied by several other groups. Functionally, AIBP has been described as an epimerase that converts R-NADHX to biologically useful S-NADHX. 4 Recent studies have suggested that NAXE protein or AIBP participates in metabolite repair, one part of a set of dedicated systems used by cells to rescue damaged metabolites. 5 In the absence of NAXE protein, there is an increase in cyclic NADHX that has been shown to inhibit cellular NADH dehydrogenases. [6] [7] [8] Two splice variants of AIBP are synthesized with the longer form predicted to reside in the mitochondria and the shorter form remaining in the cytosol. 7 As an indication of its importance, mutations in the APOA1BP gene are associated with lethal neurometabolic disorders of childhood. 6, 9 There is controversy on whether AIBP is exclusively intracellular or secreted, with Ritter et al 10 demonstrating its presence in urine, cerebrospinal fluid, and in the serum of some septic patients but not in the serum of healthy patients. HepG2 (human hepatocellular carcinoma G2) cells were also reported to secrete small amounts of AIBP.
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Conclusion
The specific mechanism of action for the protein product from APOA1BP or NAXE needs to be clarified. At first glance, the functions of AIBP described by different groups seem to be inconsistent with a unified mechanism of action that explains all of the experimental details. However, hypoxia is reported to promote angiogenesis, and the hypoxic state may also be one in which there are insufficient levels of reducing agents
